Department of OB/Gyn, University Breast Center Franconia, Univeristy Hospital Erlangen, Erlangen, Germany.
Breast Cancer Res Treat. 2010 May;121(1):101-10. doi: 10.1007/s10549-010-0845-8. Epub 2010 Mar 21.
It has been shown in several studies that antihormonal compounds can offer effective prophylactic treatment to prevent breast cancer. In view of the low participation rates in chemoprevention trials, the purpose of this study was to identify the characteristics of women taking part in a population-based mammography screening program who wished to obtain information about the risk of breast cancer and then participate in the the International Breast Cancer Intervention Study II (IBIS-II) trial, a randomized double-blind controlled chemoprevention trial comparing anastrozole with placebo. A paper-based survey was conducted in a population-based mammography screening program in Germany between 2007 and 2009. All women who met the criteria for the mammography screening program were invited to complete a questionnaire. A total of 2,524 women completed the questionnaire, and 17.7% (n = 446) met the eligibility criteria for the IBIS-II trial after risk assessment. The women who wished to receive further information about chemoprevention were significantly younger (P < 0.01) and had significantly more children (P = 0.03) and significantly more relatives with breast cancer (P < 0.001). There were no significant differences between the participants with regard to body mass index or hormone replacement therapy. Normal mammographic findings at screening were the main reason (42%) for declining to participate in the IBIS-II trial or attend risk counseling. The ultimate rate of recruitment to the IBIS-II trial was very low (three women). Offering chemoprevention to women within a mammography screening unit as part of a paper-based survey resulted in low participation rates for both, the survey and the final participation in the IBIS-II trial. More individualized approaches and communication of breast cancer risk at the time of the risk assessment might be helpful to increase the participation and the understanding of chemopreventive approaches.
几项研究表明，抗激素化合物可以提供有效的预防治疗，以预防乳腺癌。鉴于化学预防试验的参与率较低，本研究的目的是确定参与基于人群的乳房 X 线筛查计划的女性的特征，这些女性希望获得有关乳腺癌风险的信息，然后参与国际乳腺癌干预研究 II（IBIS-II）试验，这是一项比较阿那曲唑与安慰剂的随机、双盲、对照化学预防试验。2007 年至 2009 年，在德国的一个基于人群的乳房 X 线筛查计划中进行了纸质问卷调查。所有符合乳房 X 线筛查计划标准的女性都被邀请填写问卷。共有 2524 名女性完成了问卷，经过风险评估后，有 17.7%（n=446）符合 IBIS-II 试验的入选标准。希望获得更多关于化学预防信息的女性明显更年轻（P < 0.01），生育的孩子明显更多（P = 0.03），且有乳腺癌亲属的明显更多（P < 0.001）。参与者之间在体重指数或激素替代疗法方面没有显著差异。筛查时正常的乳房 X 线表现是拒绝参加 IBIS-II 试验或参加风险咨询的主要原因（42%）。IBIS-II 试验的最终招募率非常低（仅 3 名女性）。在乳房 X 线筛查单位提供化学预防作为纸质调查的一部分，导致调查和最终参与 IBIS-II 试验的参与率都很低。在进行风险评估时，采用更个体化的方法和沟通乳腺癌风险，可能有助于提高参与度和对化学预防方法的理解。
